Serious adverse events 48 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes serious adverse events 48 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Non‐serious adverse events 43 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes non‐serious adverse events 43 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Serious adverse events · patients with chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IgE mAb (omalizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) may leads to lower serious adverse events compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
1 finding from 1 review
Serious adverse events WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in serious adverse events WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Adults with plantar heel pain¹
1 finding from 1 review
Intervention not reported
Serious adverse events · people with pressure ulcers
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children with chronic asthma
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children with chronic asthma
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic asthma
LABA + ICS showed no clear difference in serious adverse events compared with LTRA + ICS (moderate certainty).
1 finding from 1 review
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Intervention not reported
Non‐serious adverse events · people with pressure ulcers
The intervention may leads to higher non‐serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Serious adverse events 17 weeks · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found